Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder

Human Pathology

Volumn 45, Issue 7, 2014, Pages 1496-1503

  Mangrud, Ok Målfrid ^a,b   Gudlaugsson, Einar ^a   Skaland, Ivar ^a   Tasdemir, Ilker ^a   Dalen, Ingvild ^a   Van Diermen, Bianca ^a   Baak, Jan P A ^a,b   Janssen, Emiel A M ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Grading; Prognostic value; Reproducibility; Urinary bladder; Urothelial carcinoma

Indexed keywords

HISTONE H3; KI 67 ANTIGEN; PHOSPHOHISTONE H3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; MITOSIS RATE; MITOTIC ACTIVITY INDEX; NON MUSCLE INVASIVE BLADDER CANCER; POPULATION BASED CASE CONTROL STUDY; PREDICTION; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; WORLD HEALTH ORGANIZATION;

GRADING; PROGNOSTIC VALUE; REPRODUCIBILITY; URINARY BLADDER; UROTHELIAL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL PROLIFERATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84903165320     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.03.001     Document Type: Article

References (31)

1. J.N. Eble, G. Sauter, J.I. Epstein, and I.A. Sesterhenn World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs 2004 IARC Press Lyon, France 110 123
2. Z. Kirkali, T. Chan, and M. Manoharan et al. Bladder cancer: epidemiology, staging and grading, and diagnosis Urology 66 6 Suppl 1 2005 4 34 (Pubitemid 43049607)
3. P. Larsson, H. Wijkstrom, and A. Thorstenson et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years Scand J Urol Nephrol 37 2003 195 201 doi:8DX5C7F06FF25E1F [pii] (Pubitemid 36791815)
4. S. Holmang, H. Hedelin, C. Anderstrom, and S.L. Jonasson The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years J Urol 153 1995 1823 1826 [discussion 26-7] doi: S0022-5347(01)67321-X [pii]
5. M. Babjuk, M. Burger, and R. Zigeuner et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013 Eur Urol 64 2013 639 653 10.1016/j.eururo.2013.06.003
6. J.I. Epstein, M.B. Amin, V.R. Reuter, and F.K. Mostofi The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee Am J Surg Pathol 22 1998 1435 1448 (Pubitemid 28550639)
7. B. Tuna, K. Yorukoglu, and E. Duzcan et al. Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility Virchows Arch 458 2011 659 664 10.1007/s00428-011- 1072-3
8. I.I. Gonul, A. Poyraz, and C. Unsal et al. Comparison of 1998 WHO/ISUP and 1973 WHO classifications for interobserver variability in grading of papillary urothelial neoplasms of the bladder. Pathological evaluation of 258 cases Urol Int 78 2007 338 344 (Pubitemid 46725706)
9. M.G. Bol, J.P. Baak, and S. Buhr-Wildhagen et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder J Urol 169 2003 1291 1294 10.1097/01.ju.0000055471.78783.ae (Pubitemid 36323769)
10. M.G. Bol, J.P. Baak, and P.C. de Bruin et al. Improved objectivity of grading of T(A,1) transitional cell carcinomas of the urinary bladder by quantitative nuclear and proliferation related features J Clin Pathol 54 2001 854 859 (Pubitemid 33063492)
11. M.G. Bol, J.P. Baak, and S. Rep et al. Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder Urology 60 2002 1124 1130 doi: S0090429502019064 [pii] (Pubitemid 35447592)
12. S. Gunia, C. Kakies, A. Erbersdobler, S. Koch, and M. May Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa J Clin Pathol 65 2012 715 720 10.1136/jclinpath-2011-200532
13. B.W. vanRhijn, A.N. Vis, and T.H. van der Kwast et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome J Clin Oncol 21 2003 1912 1921 10.1200/JCO.2003.05.073 JCO.2003.05.073 [pii] (Pubitemid 46606378)
14. I. Skaland, E.A. Janssen, and E. Gudlaugsson et al. Validating the prognostic value of proliferation measured by phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age Breast Cancer Res Treat 114 2009 39 45 10.1007/s10549-008-9980-x
15. E. Gudlaugsson, I. Skaland, and E.A. Janssen et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer Histopathology 61 2012 1134 1144 10.1111/j.1365-2559.2012.04329.x
16. M.G. Bol, J.P. Baak, and B. van Diermen et al. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks J Clin Pathol 56 2003 447 452 (Pubitemid 36724213)
17. A. Pich, L. Chiusa, and A. Formiconi et al. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder Cancer 95 2002 784 790 10.1002/cncr.10733 (Pubitemid 34839670)
18. T.T. Schimming, F. Grabellus, and M. Roner et al. pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas Am J Dermatopathol 34 2012 266 269 10.1097/DAD.0b013e31823135a3
19. P.S. Nielsen, R. Riber-Hansen, T.O. Jensen, H. Schmidt, and T. Steiniche Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma Mod Pathol 26 2013 404 413 10.1038/modpathol.2012.188
20. J.W. Oosterhuis, R.F. Schapers, M.L. Janssen-Heijnen, A.W. Smeets, and R.P. Pauwels MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors Cancer 88 2000 2598 2605 (Pubitemid 30331969)
21. A. Quintero, J. Alvarez-Kindelan, and R.J. Luque et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder J Clin Pathol 59 2006 83 88 10.1136/jcp.2004.022939 (Pubitemid 43076244)
22. Y. Lotan, A. Bagrodia, and N. Passoni et al. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy Eur Urol 64 2013 465 471 10.1016/j.eururo.2013.03.043
23. W. Otto, S. Denzinger, and H.M. Fritsche et al. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients Clin Genitourin Cancer 11 2013 537 544
24. S. Holmang, P. Andius, H. Hedelin, K. Wester, C. Busch, and S.L. Johansson Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy J Urol 165 2001 1124 1128 [discussion 28-30] (Pubitemid 32210217)
25. W. Yin, N. Chen, and Y. Zhang et al. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder Mod Pathol 19 2006 1487 1497 10.1038/modpathol.3800675 (Pubitemid 44624169)
26. M.Y. Polley, S.C. Leung, and L.M. McShane et al. An international ki67 reproducibility study J Natl Cancer Inst 105 2013 1897 1906 10.1093/jnci/djt306
27. M. Hoglund On the origin of syn- and metachronous urothelial carcinomas Eur Urol 51 2007 1185 1193 10.1016/j.eururo.2006.11.025 [discussion 93] (Pubitemid 46436302)
28. H. Han, E.M. Wolff, and G. Liang Epigenetic alterations in bladder cancer and their potential clinical implications Adv Urol 2012 2012 546917 10.1155/2012/546917
29. C. Billerey, D. Chopin, and M.H. Aubriot-Lorton et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors Am J Pathol 158 2001 1955 1959 10.1016/S0002-9440(10)64665-2 (Pubitemid 32545179)
30. B.W. van Rhijn, T.H. van der Kwast, and A.N. Vis et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma Cancer Res 64 2004 1911 1914 (Pubitemid 38339432)
31. T. Cheng, B. Roth, W. Choi, P.C. Black, C. Dinney, and D.J. McConkey Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting PLoS One 8 2013 e57284 10.1371/journal.pone.0057284